Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Annual screening for ovarian cancer has the potential to be cost effective, particularly in high-risk populations. Clinically acceptable positive predictive values are achieved if specificity exceeds 99%. Mortality reduction above 50% may not be achievable without screening intervals less than 12 months.
The miR-33b suppresses HCC cell proliferation through down-regulation of SALL4.